Anzeige
Mehr »
Login
Mittwoch, 30.10.2024 Börsentäglich über 12.000 News von 675 internationalen Medien
Desert Gold Ventures: Diese Goldaktie ist ein TOP-Übernahmekandidat
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D6JG | ISIN: US63903P1003 | Ticker-Symbol:
NASDAQ
29.10.24
18:20 Uhr
0,132 US-Dollar
0,000
0,00 %
1-Jahres-Chart
NATURES MIRACLE HOLDING INC Chart 1 Jahr
5-Tage-Chart
NATURES MIRACLE HOLDING INC 5-Tage-Chart
PR Newswire
64 Leser
Artikel bewerten:
(0)

Nature's Miracle Holding Inc.: Nature's Miracle Reports Second Quarter 2024 Financial Update

Second Quarter Revenue Increased 75% YoY and 54% Sequentially to $3.4 Million

New Distribution Agreements for Complementary Products and Product Launches Enhance Portfolio

ONTARIO, Calif., Aug. 16, 2024 /PRNewswire/ -- Nature's Miracle Holding Inc. (NASDAQ: NMHI) ("Nature's Miracle" or the "Company"), a leader in vertical farming technology and infrastructure, today reported its financial and operational update for the second quarter ended June 30, 2024.

Second Quarter 2024 and Subsequent Business Updates

  • Revenue of $3.4 million, a 75% increase from the same period in 2023, and a 54% increase compared to the first quarter of 2024.
  • Gross margin improved 800 basis points to 13.3% from the same period in 2023.
  • Launched and completed first shipment of Efinity brand Smart Dehumidifier product.
  • Developed a strong pipeline of grow light orders within the energy rebate market with total grow light purchase orders of $5 million in July.

Management Commentary

James Li, Chairman and Chief Executive Officer of Nature's Miracle, commented, "During the first full quarter as a public company, Nature's Miracle recognized significant revenue growth, strong new order trends for our existing products and diversification of our portfolio with the launch of new products and new distribution partners. In the second quarter, we achieved revenue growth of 75% from the prior year period, which was driven by strong demand from the energy rebate market for LED grow light products and increases in our marketing team and efforts. Our 800-basis point expansion of gross margin was the result of higher margins realized through the Company's Efinity brand products, favorable pricing trends from Asian manufacturers and incentive costs to the Company for operating in the energy rebate market. Taken together, we are rapidly growing our footprint across the North American market with our vertically integrated approach of products and solutions for the CEA market."

"We are pleased with our progress through the first half of 2024, and at this early stage of development as a public company. Our strategic focus is on continuing to build a foundation of existing, new and licensed products as catalysts for revenue growth in the second half of 2024 and beyond. The record purchase orders received in July are an indication that Nature's Miracle is well positioned in the market and with our effective sales and marketing channels, we will seek to further capitalize on this momentum. A defining component of our sales and marketing efforts focuses on reinforcing our distinct position as a fully integrated provider of comprehensive vertical farms, " concluded Mr. Li.

Second Quarter 2024 Financial Summary

For the second quarter of 2024, revenue totaled $3.4 million, increasing 75% from $1.9 million in the prior year period. The increase was primarily attributable to an increase in demand of our Efinity LED light products from the energy rebate market and the increases in our sales force as catalyst for this growth.

Gross profit for the second quarter of 2024 totaled $0.5 million or 13.3% of revenue, as compared to $0.1 million or 5.2% of revenue in the prior year period. The increase in gross profit as a percentage of revenue was primarily attributable to the higher margin component of our Efinity brand products and the finance structure of the energy rebate market.

Selling, general and administrative expenses increased to $1.5 million compared to $0.5 million in the prior year period. The increase was primarily due to public company costs, higher spend on staffing related, legal, accounting and other professional fees as well as stock compensation charges.

Net loss for the second quarter of 2024 totaled $1.8 million, or $(0.07) per share, and net loss of $0.4 million, or $(0.02) per share in the prior year period.

Cash and cash equivalents totaled $30,532 at June 30, 2024, compared to $221,760 at December 31, 2023. Subsequent to quarter end, on July 29, 2024, the company closed a public offering for aggregate gross proceeds of $1.2 million.

About Nature's Miracle Holding Inc.

Nature's Miracle (NASDAQ: NMHI) is a growing agriculture technology company providing equipment and services to growers in the Controlled Environment Agriculture ("CEA") industry which also includes vertical farming in North America. Nature's Miracle offers hardware to design, build and operate various indoor growing settings including greenhouse and indoor-growing spaces. Nature's Miracle, through its two wholly-owned subsidiaries Visiontech Group, Inc. and Hydroman, Inc., provides grow lights as well as other hydroponic products to hundreds of indoor growers in North America. For more information visit www.Nature-Miracle.com.

Forward-Looking Statements

The information in this press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "forecast," "intends," "may," "will," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: the intended use of proceeds from the offering; successful launch and implementation of Nature's Miracle's joint projects with manufacturers and other supply chain participants of steel, rubber and other materials; changes in Nature's Miracle's strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; Nature's Miracle's ability to develop and launch new products and services; Nature's Miracle's ability to successfully and efficiently integrate future expansion plans and opportunities; Nature's Miracle's ability to grow its business in a cost-effective manner; Nature's Miracle's product development timeline and estimated research and development costs; the implementation, market acceptance and success of Nature's Miracle's business model; developments and projections relating to Nature's Miracle's competitors and industry; and Nature's Miracle's approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company's shares on Nasdaq; changes in applicable laws or regulations; the effects of the coronavirus (COVID-19) and any future outbreaks on Nature's Miracle's business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which Nature's Miracle's operates; the risk that Nature's Miracle's and its current and future collaborators are unable to successfully develop and commercialize Nature's Miracle's products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that Nature's Miracle's is unable to secure or protect its intellectual property; the possibility that Nature's Miracle's may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in Nature's Miracle's filings from time to time with the SEC.

Contacts
George Yutuc
Chief Financial Officer
[email protected]

MZ North America
Shannon Devine / Rory Rumore
Main: 203-741-8811
[email protected]

NATURE'S MIRACLE HOLDING INC., SUBSIDIARIES AND VIE

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS






For the Three Months Ended


For the Three Months Ended

For the Six Months Ended

For the Six Months Ended





June 30,


June 30,

June 30,

June 30,





2024


2023

2024

2023





(Unaudited)


(Unaudited)

(Unaudited)

(Unaudited)

REVENUE



$

3,404,967


$

1,943,528

$

5,609,687

$

4,910,200

COST OF REVENUE



2,952,747



1,843,257


4,845,150


4,512,669

GROSS PROFIT



452,220



100,271


764,537


397,531














OPERATING EXPENSES:












Selling, general and administrative



1,540,983



458,037


2,684,120


1,015,046


Stock compensation expenses



195,908



-


367,805


-



Total operating expenses



1,736,891



458,037


3,051,925


1,015,046

LOSS FROM OPERATIONS



(1,284,671)



(357,766)


(2,287,388)


(617,515)

OTHER EXPENSES












Interest (expense) income, net



(486,586)



38,890


(788,975)


(360,020)


Non cash finance expense



-



-


(1,000,000)


-


Loss on loan extinguishment



-



(233,450)


-


(233,450)


Other expenses



3,738



6,716


3,738


6,346



Total other expense, net



(482,848)



(187,844)


(1,785,237)


(587,124)

LOSS BEFORE INCOME TAXES



(1,767,519)



(545,610)


(4,072,625)


(1,204,639)

PROVISION FOR (BENEFIT OF) INCOME TAXES



800



(139,040)


2,500


(230,690)

NET LOSS


$

(1,768,319)


$

(406,570)

$

(4,075,125)

$

(973,949)

OTHER COMPREHENSIVE LOSS












Foreign currency translation adjustment



(83)



(65)


(33)


791

COMPREHENSIVE LOSS


$

(1,768,402)


$

(406,635)

$

(4,075,158)

$

(973,158)

WEIGHTED AVERAGE NUMBER OF COMMON STOCK*










Basic and diluted



26,458,515



22,272,478


24,793,466


22,272,478

LOSS PER SHARE












Basic and diluted


$

(0.07)


$

(0.02)

$

(0.16)

$

(0.04)

UNAUDITED CONDENSED BALANCE SHEET







As of June 30,


As of Dec 31,






2024


2023






(Unaudited)




ASSETS







CURRENT ASSETS








Cash and cash equivalent


$

30,532


$

221,760


Accounts receivable, net



2,053,678



1,236,248


Accounts receivable - related parties, net



717,835



305,669


Inventories, net



4,169,333



5,046,084


Prepayments and other current assets



347,465



139,734


Loans receivable - related parties



-



460,000



Total Current Assets



7,318,843



7,409,495











NON-CURRENT ASSETS








Security deposit



27,633



47,633


Right-of-use assets, net



578,179



503,089


Cost method investment



1,000,000



1,000,000


Property and equipment, net



4,326,552



4,406,272


Deferred offering costs



-



833,932




Total Assets


$

13,251,207


$

14,200,421











LIABILITIES AND STOCKHOLDERS' EQUITY











CURRENT LIABILITIES








Short-term loans


$

2,928,183


$

509,443


Short-term loans - related parties



908,255



783,255


Current portion of long-term debts



284,493



268,805


Accounts payable



8,875,916



8,034,044


Accounts payable - related parties



2,713,074



2,758,074


Other payables and accrued liabilities



3,385,079



1,351,951


Other payables - related parties



292,157



257,954


Operating lease liabilities - current



460,311



359,459


Tax accrual



452,725



340,628


Deferred income - Contract liabilities



64,069



118,909



Total Current Liabilities



20,364,262



14,782,522

NON-CURRENT LIABILITIES








Long-term debts, net of current portion



5,833,562



5,979,939


Operating lease liabilities, net of current portion



184,147



157,897



Total Non-Current Liabilities



6,017,709



6,137,836




Total Liabilities



26,381,971



20,920,358











COMMITMENTS AND CONTINGENCIES

















SHAREHOLDERS' DEFICIT








Preferred Stock ($0.0001 par value, 1,000,000 shares authorized, none issued and






outstanding at June 30, 2024 and December 31, 2023, respectively)


-



-


Common Stock ($0.0001 par value,100,000,000 shares authorized, 26,456,764 and 22,272,478






shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively)*

2,645



2,227


Additional paid-in capital



1,894,563



1,526,773


Accumulated deficit



(15,026,864)



(8,247,862)


Accumulated other comprehensive loss



(1,108)



(1,075)



Total Stockholders' Deficit



(13,130,764)



(6,719,937)














Total Liabilities and Stockholders' Deficit


$

13,251,207


$

14,200,421

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS







For the Six Months Ended


For the Six Months Ended






June 30,


June 30,






2024


2023






(Unaudited)


(Unaudited)

CASH FLOWS FROM OPERATING ACTIVITIES:







Net loss

$

(4,075,125)


$

(973,949)


Adjustments to reconcile net income to net cash used in








operating activities:









Depreciation expense


79,720



83,388




Allowance for credit losses


24,391



789




Amortization of operating right-of-use asset


155,295



204,732




Amortization of debt issuance cost


-



73,782




Deferred taxes benefits


-



(242,908)




Loss on loan extinguishment


-



233,450




Loss on early termination of right-of-use asset


-



33,423




Stock compensation expenses


367,805



-




Non cash finance expense


1,000,000



-



Change in operating assets and liabilities:









Accounts receivable


(1,253,986)



(105,364)




Inventories


876,751



2,242,101




Prepayments and other current assets


(207,731)



89,676




Security deposit


20,000



49,960




Accounts payable


796,876



(1,775,240)




Other payables and accrued liabilities


485,314



(68,251)




Accrued interest payable - related parties


34,203



26,033




Operating lease liabilities


(103,284)



(260,484)




Tax accrual


112,097



12,597




Deferred income - Contract liabilities


(54,841)



(121,006)





Net cash used in operating activities


(1,742,515)



(497,271)

CASH FLOWS FROM INVESTING ACTIVITIES:







Proceeds from the reverse recapitalization


1,120,177



-


Payments of transaction costs incurred by Lakeshore


(1,044,980)



-


Repayments of promissory note - related party of Lakeshore


(75,000)



-


Loan to related parties


-



(150,000)


Loan to Lakeshore


(40,000)



-


Loan repayment from third parties


-



132,913





Net cash used in investing activities


(39,803)



(17,087)

CASH FLOWS FROM FINANCING ACTIVITIES:







Payments of deferred offering costs


(266,925)



(533,929)


Long-term loan borrowing


-



3,338,546


Repayments on long-term loan


(130,689)



(54,999)


Short-term loan borrowing from third parties


2,487,500



4,812


Repayments on short-term loan from third parties


(498,760)



(1,763,814)


Short-term loan borrowing from related parties


-



773,255


Repayments on short-term loan from related parties


-



(700,000)


Borrowings from other payables - related parties


-



1,000





Net cash provided by financing activities


1,591,126



1,064,871

EFFECT OF FOREIGN EXCHANGE ON CASH


(36)



792

CHANGES IN CASH


(191,228)



551,305

CASH AND CASH EQUIVALENT, beginning of period


221,760



810,371

CASH AND CASH EQUIVALENT, end of period

$

30,532


$

1,361,676

SOURCE Nature's Miracle Holding Inc.

© 2024 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.